RFK Jr. Is Supporting mRNA Research—Just Not for Vaccines

One of the target recipients, Tiba Biotech had a $ 750,000 deal with the borders that could end on October 30. RNAI refers to short pieces of RNA for intervention and small pieces of RNA that can stop production of certain proteins. The method is well studied, and several RNAI-based drugs are in the market. The first one was approved for the treatment of nerve damage due to a rare disease called hereditary tranteretein-mediocre amyloidosis.

The cancellation of the contract was surprised by the TIA, which received the stop-work order on August 5, which did not mention the air-down of the Bardar MRNA vaccine development program. “Our project is not involved in the development of MRNA products and it is more than a vaccine,” said Jasdev Chahal, Chief Scientific Officer of TB through email.

Government agreements often include specific milestones that contractors must receive funds and achieve them to move forward with their projects. Tiba says that its project has met its goals so far and it was close to finishing.

The cancellation agreement also had 50 750,000 rewards to convert MRNA-based antiviral treatment flu and covid into an inhaled, dried powder formation. The project was not involved in the development of any vaccine. “Unfortunately, we do not have much insight to cancel the grant,” Emri spokesman Brian Katzovits told Ward.

Cuts are consistent with Kennedy’s desire to deprive the study in infectious diseases, although Experts have warned That they may leave the United States more risky in future epidemics.

The administration has expressed enthusiasm about some covid research involving the MRNA even after the RNA-related infectious disease research was reduced.

In January, after taking charge, President Trump announced a joint venture with Open, Oracle and Softbank to invest up to $ 500 billion for AI infrastructure for AI infrastructure. At that time, Oracle CEO Larry Ellison talked about the possibility of producing personalized MRNA-based vaccines for cancer.

A Aug 12 OP-Ed National Health Director J Bhattacharya has acknowledged the MRNA’s promise in the Washington Post. He wrote, “I do not debate about the possibility of it. In the future it can still provide progress in the treatment of diseases like cancer and continues to invest on the ongoing research on HHS oncology and other complex diseases,” he wrote.

In contrast to his boss, Bhattacharya says he does not believe that MRNA vaccines have done great damage. However, he says that the reason for stopping the MRNA vaccine research is that the platform has lost public confidence – this is an argument that deviates from Kennedy.

Nevertheless, MRNA may be even more acceptable when treating very ill patients with genetic disorder comes.

Early this year GreenLit is a customized gene-editing treatment For a baby named Muldun with rare and deadly liver disease. Made in just six months, it uses MRNA to provide gene-editing materials in its liver. It was used for the first time a customized gene-editing treatment was used to treat a patient successfully.

In June, FDA Commissioner Marti Makery Achievement Opened Her podcastIt called “a big win for medical science” and a FDA roundtable The company said the company would continue to facilitate the regulatory process for such products.

Researchers have met with the FDA on the plan of planning planning plans for planning the same method for more patients behind custom gene-editing treatment. “The FDA was very positive about the proposal and gave the green light to our work effectively,” Kiran Musunuru, a professor of translation research at the University of Pennsylvania, said and Professor of Children’s Hospital in Philadelphia.

This team has another meeting with the FDA in one or two months to discuss the concept of a platform outside a single disease or a single gene. “We will see how we look,” he said.